Initial Statement of Beneficial Ownership (3)
January 11 2021 - 4:50PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Lentini Renee |
2. Date of Event Requiring Statement (MM/DD/YYYY)
1/1/2021
|
3. Issuer Name and Ticker or Trading Symbol
ImmunoGen, Inc. [IMGN]
|
|
(Last)
(First)
(Middle)
830 WINTER STREET |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
V.P.-Fin., Prin. Acctg. Off. / |
|
(Street)
WALTHAM, MA 02451
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4) | 2. Amount of Securities Beneficially Owned
(Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) | 4. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Common Stock | 12148 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4) | 2. Date Exercisable and Expiration Date
(MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) | 6. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Stock Option (Right to buy) | 7/22/2012 (1) | 7/22/2021 | Common Stock | 9000 | $15.20 | D | |
| Stock Option (Right to buy) | 7/20/2013 (1) | 7/20/2022 | Common Stock | 9000 | $15.83 | D | |
| Stock Option (Right to buy) | 7/16/2014 (1) | 7/16/2023 | Common Stock | 9000 | $19.02 | D | |
| Stock Option (Right to buy) | 7/17/2015 (1) | 7/17/2024 | Common Stock | 9000 | $10.79 | D | |
| Stock Option (Right to buy) | 7/13/2016 (1) | 7/13/2025 | Common Stock | 8250 | $16.72 | D | |
| Stock Option (Right to buy) | 7/18/2017 (1) | 7/18/2026 | Common Stock | 11500 | $3.05 | D | |
| Stock Option (Right to buy) | 9/30/2017 (1) | 9/30/2026 | Common Stock | 19000 | $2.68 | D | |
| Stock Option (Right to buy) | 2/21/2018 (1) | 2/21/2027 | Common Stock | 6000 | $2.47 | D | |
| Stock Option (Right to buy) | 2/15/2019 (2) | 2/15/2028 | Common Stock | 23000 | $10.65 | D | |
| Stock Option (Right to buy) | 1/31/2020 (2) | 1/31/2029 | Common Stock | 36400 | $5.25 | D | |
| Stock Option (Right to buy) | 7/18/2020 (3) | 7/18/2029 | Common Stock | 69000 | $2.31 | D | |
| Stock Option (Right to buy) | 2/7/2021 (3) | 2/7/2030 | Common Stock | 52440 | $4.55 | D | |
| Explanation of Responses: |
| (1) | All options are exercisable as of the filing date of this Form 3. |
| (2) | Exercisable in three equal installments over three years starting on the first year anniversary of the grant. |
| (3) | 25% of the options are exercisable on the first year anniversary of the grant and the balance is exercisable in twelve equal installments of 6.25%, quarterly over the following three years starting one quarter after the first year anniversary. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Lentini Renee
830 WINTER STREET
WALTHAM, MA 02451 |
|
| V.P.-Fin., Prin. Acctg. Off. |
|
Signatures
|
| /s/ Renee Lentini | | 1/11/2021 |
| **Signature of Reporting Person | Date |
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024
